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ABSTR ACT: Ganoderma lucidum (lingzhi) has been used for the general promotion of health in Asia for many centuries. The common method of 
consumption is to boil lingzhi in water and then drink the liquid. In this study, we examined the potential anticancer activities of G. lucidum submerged in 
two commonly consumed forms of alcohol in East Asia: malt whiskey and rice wine. The anticancer effect of G. lucidum, using whiskey and rice wine-based 
extraction methods, has not been previously reported. The growth inhibition of G. lucidum whiskey and rice wine extracts on the prostate cancer cell lines, 
PC3 and DU145, was determined. Using Affymetrix gene expression assays, several biologically active pathways associated with the anticancer activities 
of G.  lucidum extracts were identified. Using gene expression analysis (real-time polymerase chain reaction [RT-PCR]) and protein analysis (Western 
blotting), we confirmed the expression of key genes and their associated proteins that were initially identified with Affymetrix gene expression analysis.
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Introduction
Ganoderma lucidum is a bitter fungus with a glossy exterior 
and a woody texture.1 It is commonly referred to as “lingzhi” 
in China and has been used in most Asian countries for the 
promotion of health and longevity for centuries.1–3 Numer-
ous pharmacological effects associated with lingzhi have 
been recorded, which include immunomodulating,4 anti-
inflammatory,5 antitumor,6–8 radioprotective,9 antiviral,10 
antioxidative,6–8 and antiaging6–8 properties.
Several studies have shown that G.  lucidum contains a 
wide range of bioactive compounds associated with the pro-
motion of good health.1,2,4–14 These bioactive compounds can 
be extracted via water-based or ethanol-based extraction meth-
ods.8,15 The extraction process is very important for consump-
tion of G. lucidum as the fungus is tough and indigestible by 
humans. There are many ways to consume G. lucidum;8,15 one 
method of consumption is to submerge the fungus in alcoholic 
beverages for a prolonged period of time. Since alcoholic bever-
ages contain both water and ethanol components, this method 
can potentially extract the active ingredients of G. lucidum asso-
ciated with both solvents.16 Various extracts of G. lucidum have 
been shown to have anticancer effects in both in vivo (mouse 
model) and in vitro (cancer cell lines) studies.8,17 These include 
cytotoxic,18,19 antimetastatic,20–22 and immune-modulating23–26 
effects. Therefore, G. lucidum is an interesting plant extract that 
has been widely used in alternative medicine and1–3 proven to 
have numerous implications to be used as a potential anticancer 
drug; however, still much research needs to be done to quan-
tify it for personalized medicine, especially in treating specific 
cancers such as prostate cancer (PCa).
Currently, PCa is the most commonly diagnosed cancer 
in males in Australia and New Zealand and the fifth most 
common cancer worldwide.27 Human cell lines are commonly 
used as models of PCa. There are several commonly available 
PCa cell lines that differ in their molecular properties. Two 
PCa cell lines were used in this study: PC3 and DU145. Both 
are aggressive and androgen-independent forms of PCa, with 
PC3, and not DU145, still retaining the coregulators required 
for Androgen-dependent tumor suppression.28 The  aim of 
this study is to identify any potential anticancer effect of 
G.  lucidum extracts in PCa with in vitro cell culture tests. 
In addition, the biologically active pathways associated with 
the observed activities were determined using various gene/
protein expression analyses, including Affymetrix, real-time 
polymerase chain reaction (RT-PCR), and Western blotting 
(WB). WB, the detection of proteins using specific antibod-
ies, has been used to detect the expression levels of specific 
proteins in tumors after treatment with G. lucidum.29,30
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Method
Preparation of G. lucidum alcohol extract. The G. lucidum 
alcohol extracts tested in this study were provided by NZFo-
cus. The extract contained dried G. lucidum from the Himalayan 
region (Fig. 1) submerged in either whiskey (13-year-old single 
malt scotch whiskey, D. Johnston & Co.) or rice wine (Pearl 
River Bridge, Guandong PRB Bio-Tech Co.) for six months. 
G. lucidum was then removed from the alcohol extracts. After 
the extraction processes, the extracts were stored in room tem-
perature in darkness and were then examined for any potential 
anticancer activity in human PCa cell lines. Controls are listed 
in Table 1. G.  lucidum submerged in whiskey or rice wine is 
referred to as G. lucidum whiskey extract (GWh) or G. lucidum 
rice wine extract (GRW), respectively. The positive control 
used in this study was azathioprine (Sigma-Aldrich). Azathio-
prine, owing to its property of inhibiting DNA synthesis and 
cell proliferation,31,32 is a cytotoxic drug used for the treatment 
of several diseases, including cancer.
Cell culture. Cryopreserved PCa cell lines (DU145-
HTB-81™; PC3-CRL-1435™) were purchased from 
American Type Culture Collection. Experimental work was 
carried out within three months of cell thawing. The media 
used and the doubling times of the cell lines are shown in 
Supplementary Table 1. The cell lines were grown in 25 mL 
Becton Dickinson Falcon™ cell culture flasks (BD Biosci-
ences) at 37°C with 5% CO2.
Growth inhibitory assays. The cells were harvested 
when they reached 90% confluence. All cell lines were seeded 
at a cell density of 2,000 cells/well in 96-well plates (Corn-
ing Incorporated) and incubated overnight at 37°C with 5% 
CO2 before being treated with the aforementioned extracts 
(Table 1). The cells were incubated under the same conditions 
for four doubling cycles. Growth inhibition was measured 
using the sulforhodamine B-based assay.33 Using results from 
the growth inhibition assays, the optimal dosing range was 
determined. Four technical repeats and two biological repeats 
were performed. Standard curve analysis was calculated using 
Sigma plot 11.0 (Systat Software Inc.), and the 50% inhibition 
of proliferation (IC50) values of each extract in each cell line 
were determined using a standard curve.
RNA extraction, quantitation, and qualification. The 
cell lines were treated for four doubling cycles with G. lucidum 
extracts and controls at established IC50 dosages. Thereafter, 
RNA was isolated using an RNeasy Plus Mini Kit ( Qiagen). 
The concentration and purity of the RNA samples were 
assessed using a NanoDrop® ND-1000 Spectrophotometer 
(Thermo Fisher Scientific).
The integrity of the RNA sample was checked using an 
Agilent 2100 bioanalyzer (Agilent Technologies, Inc.) using 
facilities at the School of Biological Sciences, The University 
of Auckland. Each RNA sample had a minimum RNA integ-
rity number of 9.5 or higher, indicating that the RNA samples 
had not degraded. Technical triplicates were performed per 
extract per cell line.
Affymetrix analysis. The GeneChip® PrimeView™ 
Human Gene Expression Array (Affymetrix) was used to 
measure the gene expression profile of each selected can-
cer cell line after treatment with the extracts and control 
solvents. The expression of more than 20,000 genes using 
530,000 probes covering 36,000 transcripts and variants was 
measured.34 Each probe set contains 20 probes targeting dif-
ferent sequences of the same gene.34 Three repeats per sample 
were used for Affymetrix gene expression analysis.
The expression level of genes is associated with the absor-
bance values of the probes targeting each specific gene.34 The 
media-only treatment was considered as a negative control for 
this study as it represented the normal level of gene expres-
sion. The gene expression levels after treatment with GWh or 
GRW were compared with media-only control to calculate the 
changes in gene expression as a result of G. lucidum treatment 
using the extracts. Furthermore, the changes in gene expres-
sion levels were adjusted with the whiskey-only and rice wine-
only controls. This removed the changes in gene expression 
levels due to the alcohol solvents in the G. lucidum extracts.
Statistical analysis. R software35 was used for the anal-
ysis of Affymetrix data. Data were normalized using robust 
multiarray average approach. Significance was calculated 
using limma t-statistic with adjustments to alcohol-only con-
trol samples. P-value was adjusted using “fdr” as included in 
the limma package, where fdr is the Benjamini and Hoch-
berg’s method to control the false discovery rate.36
The data generated from the Affymetrix analysis were 
filtered based on the level of statistical significance. A pre-
specified P-value was set at 0.01 for statistical significance. 
Any probes with an adjusted P-value greater than 0.01 after 
adjustment for alcohol consumption were removed from fur-
ther analysis. R was used for statistical analyses.37
After the removal of probes, further analysis was done 
separately for up- and downregulated genes to investigate 
these differentially expressed genes. The genes with greater 
than twofold changes in expression were selected for pathway 
analyses to help identify the most strongly affected pathways.
Pathway analyses, gene annotation tool to help explain 
relationships (GATHER) (http://gather.genome.duke.edu/), 
Figure 1. Wild G. lucidum from the Himalayan region grown on the base 
of deciduous tree. Photo courtesy of NZFocus Ltd.
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and PathVisio 3.1.2 (www.pathvisio.org) were used to deter-
mine the association between gene expression levels and 
biological pathways. GATHER is specialized in determin-
ing the strength of association between genes and pathways. 
PathVisio is specialized in portraying the interactions between 
genes within the pathways of interest.
RT-PCR. RNA was converted to cDNA using a 
Quantitect Reverse Transcription Kit (Qiagen). The expres-
sion levels of 28 genes, based on fold change and pathway anal-
ysis, were determined using RT-PCR (Custom TaqMan array 
card, Thermo Fisher Scientific) in triplicate. Glyceraldehyde 
3-phosphate dehydrogenase (GAPDH), Hypoxanthine-guanine 
phosphoribosyltransferase (HPRT1), and 18S ribosomal RNA 
(18S) were used as housekeeping genes for the normalization 
of RNA expression. PCR was performed with 7900HT ther-
mocycler (Applied Biosystems), and the amplified products 
were quantified using TaqMan® probes (Invitrogen). A stan-
dard curve was calculated using comparative Ct analyses with 
SDS2.3 and RQ Manager 2.2 software from three technical 
repeats. The relative expression was calculated as fold change 
using Microsoft Excel (2010). Probes where the range of the 
maximum and minimum fold change is either .1 or ,−1 were 
considered statistically significant.
Western blotting. Protein samples were extracted by 
adding radioimmunoprecipitation assay buffer to cell culture 
and placing on ice for 15 minutes. The lysates were centrifuged 
for 15 minutes at 14,000 × g at 4°C. Protein concentrations 
in the lysates were measured using the bicinchoninic acid 
assay. A total of 20 µg of protein was loaded and electropho-
resed on a 12.5% SDS-PAGE Bolt mini gel (Novex Bolt 12% 
Bis-Tris Plus). Size standards from 3 to 188 kDa (SeeBlue® 
Plus2 Pre-stained Protein Standard Novex) were included in 
each gel.
After electroblotting, the proteins separated in the gel 
were transferred to a polyvinylidene difluoride membrane 
(Bio-Rad) using a semidry Trans-Blot® Turbo™ Blotting 
System (Bio-Rad). Membranes were stained with Ponceau 
S solution (Sigma-Aldrich) and then saturated with block-
ing buffer (5% skim milk powder in 1 × PBS-T) and incu-
bated at room temperature for one hour with gentle rocking. 
Membranes were then rinsed in PBS-T and incubated with 
primary antibody (Ab) (Supplementary Table 2) for one 
hour at room temperature. Membranes were washed three 
times in PBS-T and incubated with secondary Ab at 4°C 
overnight.
Chemiluminescence substrate, Clarity™ Western-enhanced 
chemiluminescence (Bio-Rad), was added to the membrane 
and incubated in the dark for five minutes. The membrane was 
exposed to UV and the signals were measured using image reader 
LAS-3000 (Fujifilm). The signal was quantified with Science 
Lab MultiGauge (Fujifilm).
Results
Growth inhibition of the cell lines. The growth inhibi-
tory properties of G. lucidum extracts were investigated using 
two human PCa cell lines and one noncancerous cell line as a 
control cell line.
IC50 dosages of each cell line/extract combination are 
shown in Table 2. GWh has the strongest inhibition of prolif-
eration, followed by whiskey-only and ethanol-only extracts, 
which suggests that the G.  lucidum component in GWh 
contributes to the inhibition of proliferation. In addition, 
components in whiskey also showed some inhibition of 
proliferation, although not as powerful as the GWh. GRW 
had a stronger inhibitory effect on PC3 than DU145 and 
showed stronger inhibition than rice wine-only and ethanol-
only extracts. The IC50 dosages calculated using data from 
both the G. lucidum alcohol extracts were found to be higher 
than those of the alcohol-only extracts in all the cell lines, 
except DU145. In DU145, the alcohol equivalents showed 
only slightly lower IC50 dosages than the G. lucidum extracts.
Affymetrix result. Affymetrix gene expression analysis 
has been used to identify several thousand genes with statisti-
cally significant changes in their expression levels (Table 3). 
PC3 and DU145 cell lines showed changes in expression levels 
of large number of genes associated with GWh treatment, but 
few changes in gene expression following the administration 
of GRW. HEK293, used as a control cell line, showed only a 
small number of genes with significant changes in expression 
levels following treatment with both G. lucidum extracts.
Table 1. Extract treatments and controls used to assess the growth inhibitory potential of G. lucidum extracts in PCa cell lines.
TREATMENT/CONTROL TYPE ABBREVIATION DESCRIPTION
G. lucidum in whiskey GWh In-house extraction method (NZ Focus Ltd).
Whiskey only Who Control for GWh accounting for additional components of whiskey that may 
have proliferation effects on the cell lines.
G. lucidum in rice wine GRW In-house extraction method (NZ Focus Ltd).
Rice wine only RWo Control for GRW accounting for additional components of rice wine that 
may have proliferation effects on the cell lines.
ethanol etoh Control to account for the ethanol content in the alcoholic beverages tested.
Azathioprine Aza Positive control (cell proliferation inhibitor).
Media-only control cont Negative control.
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Figure 2 shows all the genes that had statistically signifi-
cant changes in expression levels after treatment with GWh 
in PC3 and DU145 cell lines. There are 1,875 genes that have 
statistically significant changes in expression in both PC3 and 
DU145 cell lines.
The raw data of Affymetrix gene expression analysis 
are available at figshare.com/s/c702649a78ff11e5b39206ec4b 
8d1f61
Pathway analysis using GATHER. The genes identified 
to have significant changes in expression levels were submitted 
to GATHER in order to examine the relationships between 
the relevant genes and biological pathways. Lists of biologi-
cal pathways were generated and ranked based on their Bayes 
factor scores.
Table 4 shows a list of the significant pathways that 
were associated with cell cycle, DNA repair, and cancer pro-
gression. All cell lines demonstrated statistically significant 
changes in gene expression levels associated with cell cycle 
after treatment with GWh. Only PC3, and not DU145 and 
HEK293, showed strong changes in gene expression associ-
ated with DNA repair. All the three tested cell lines showed 
moderate-to-strong changes in gene expression levels associ-
ated with inflammatory response, angiogenesis, antigen pre-
sentation, and cell–cell adhesion (Table 4).
Pathway analysis using PathVisio. PathVisio is an open-
source pathway analysis and visualization software.38 Using 
PathVisio 3.1.2 and additional plugins, pathway analysis was 
performed to determine the strength of association between 
pathways and sets of genes. Table 5 shows a list of pathways 
with significant changes in gene expression after treatment 
with GWh.
Z-score is another method of presenting statistical asso-
ciation for the strength of association. In Table 5, a Z-score 
greater than 2 suggests strong association with the pathway. 
The PCa cell lines used in this study showed a strong associa-
tion with cell cycle-associated pathways, whereas HEK293, a 
noncancerous cell line, showed weak or no significant associa-
tion with the pathways listed (Table 5).
Biologically active pathways. The biologically active 
pathways associated with cancer and cancer progression 
involve complex interactions of numerous genes. Using 
GATHER, biologically active pathways with the strongest 
associations with changes in gene expression are ascer-
tained. Utilization of the PathVisio 3.1.2 program and data 
from WikiPathways (http://wikipathways.org/) allowed us 
to visualize these biological pathways in combination with 
Table 3. Number of genes with statistically significant changes in 
expression after treatment with GWh extract. All genes shown are 
after adjustment with whiskey-only and media-only controls.
PC3 DU145
UP DOWN UP DOWN
Number of genes with a statistically significant fold change  
(P , 0.05)
5152 6794 2183 2357
Number of genes with a fold change .2
598 1668 228 441
Figure 2. Number of genes with statistically significant changes in their 
expression levels after treatment with G. lucidum whiskey extract and 
adjusted with whiskey-only control. Affymetrix analysis showed that 
between PC3 and DU145 cell lines, there are 1,875 genes that had 
statistically significant changes in the expression levels in both cell lines. 
The overlap lists several genes that had undergone RT-PCR analysis to 
validate the observed expression.
Table 2. Dosages required to achieve 50% of maximum inhibition of cell proliferation.
IC50 DOSAGES (STANDARD ERROR OF ESTIMATE)
PC3 DU145 HEK293
PCa NONCANCEROUS CONTROL
Ganoderma whiskey extract 4.52 µl (3.69%) 5.81 µl (3.62%) 9.85 µl (3.53%)
Whiskey only 5.7 µl (1.76%) 4.89 µl (2.18%) 19.14 µl (4.74%)
Ganoderma rice wine extract 1.33 µl (2.99%) 4.99 µl (2.12%) 10.64 µl (1.73%)
Rice wine only 1.71 µl (4.01%) 4.75 µl (1.83%) 18.46 µl (2.88%)
ethanol 5.38 µl (2.47%) 16.92 µl (1.57%) .40 µl (0.97%)
Azathioprine 2.05 µg (2.40%) 1.68 µg (1.30%) 3.185 µg (0.83%)
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changes in gene expression levels. Figure 3 shows the inter-
actions between the genes associated with cell cycle and the 
changes in their expression level after treatment with GWh 
in the PC3 cell line. Almost all genes, including the cyclin-
dependent kinases (CDK), involved in cell cycle progression 
were discovered to be downregulated after treatment with 
GWh. CDK is a family of proteins crucial for the successful 
progression of the cell cycle.39
Figures 4 and 5 illustrate the interactions between the 
genes associated with apoptosis. Figure 4 represents the 
changes in gene expression levels of these genes after treat-
ment with GWh in the PC3 cell line. Figure 5 shows the 
changes in gene expression in the noncancerous control cell 
line, HEK293. The genes involved in the apoptotic pathway 
are either proapoptotic or antiapoptotic. PC3 shows upreg-
ulation of proapoptotic genes, including various caspases, 
while antiapoptotic genes are observed to be downregulated. 
HEK293 shows downregulation of various proapoptotic genes 
and upregulation of antiapoptotic genes.
Figure 6 illustrates the interaction between the genes 
associated with inflammatory and immune response pathways. 
The changes in gene expression levels in the PC3 cell line 
after treatment with GWh are also shown in Figure 6. The 
immune cells affected by these genes are shown in orange 
text. A strong upregulation of various cytokines associ-
ated with activation of a diverse range of immune cells was 
observed.
RT-PCR and WB. The expression levels of differ-
ent genes obtained from RT-PCR analysis were compared 
to the gene expression levels obtained from the Affymetrix 
array analysis. The comparison between gene expression levels 
obtained from the Affymetrix and RT-PCR assays by treating 
the PC3 and DU145 PCa cell lines is shown in Table 6. Most 
genes showed similar changes in expression levels between 
RT-PCR and Affymetrix analysis, with the exception of 
CDKN3 in DU145 cell line that had upregulated expres-
sion in RT-PCR analysis but downregulated expression in 
Affymetrix.
In addition, the protein expression levels were determined 
by WB. Figure 7 shows the WB bands after treatment with 
GWh, WhO, and media. Thicker bands representing greater 
levels of protein can be observed in the figure. Therefore, 
if GWh-treated bands are thicker than their media-only 
counterparts, the protein expression levels of the correspond-
ing genes are stimulated by GWh. For all the genes tested, 
their changes in protein expression levels are in the same 
direction as their gene expression changes (Fig. 8).
Discussion
Cell culture. Both the G. lucidum extracts tested showed 
significant growth inhibitory effects on both cancer cell lines 
(Table 2). At 50% growth inhibition dosages of the GWh 
and GRW, their respective solvents also showed smaller but 
observable growth inhibition (Table 2). This suggests that the 
alcoholic solvents also contributed to the observed growth 
Table 4. Pathways associated with significant changes in gene expression after treatment with GWh derived using GATHER analysis. Bayes 
factor greater than 9 (in bold) represents a significant association between biological pathway and treatment of cell lines with GWh extract. Bayes 
factors between 3 and 9 represent a small but significant association between biological pathway and treatment of cell lines with GWh extract.
G. lucidum WHISKEY EXTRACT
PC3 DU145 HEK293
GO:0007049 [5]: cell cycle 44.81 15.08 23.43
GO:0000074 [6]: regulation of cell cycle 25.52 14.64 9.36
GO:0000082 [7]: G1/S transition of mitotic cell cycle 5.99 1.99 2.05
GO:0006281 [6]: DNA repair 11.02 2.79 5.6
GO:0006260 [6]: DNA replication 16.13 0.25 2.35
GO:0000067 [6]: DNA replication and chromosome cycle 15.3 1.23 2.92
GO:0006298 [7]: mismatch repair 6.1 5.9 6.11
GO:0006954 [5]: inflammatory response 4.58 4.82 17.55
GO:0001525 [6]: angiogenesis 5.68 3.78 5.63
GO:0019882 [5]: antigen presentation 5.68 3.78 5.63
GO:0016337 [5]: cell–cell adhesion 3.88 9.49 3.92
 
Table 5. Pathways associated with significant changes in gene 
expression after treatment with GWh derived using PathVisio. Bold 
faces represent significant association between pathway and extract.
PATHWAY ABSOLUTE Z SCORE
PC3 DU145 HEK293
DNA replication 4.69 3.7 1.71
Cell cycle 4.46 2.91 1.6
G1 to S cell cycle control 3.79 2 0.75
DNA damage response 3.19 1.75 1.6
Integrated cancer pathway 3.58 0.37 0.53
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Table 6. Comparison of the changes in the fold change of gene expression levels after treatment with G. lucidum whiskey extract between 
Affymetrix and RT-PCR. The genes are separated into different biological pathways as classified by GATHER genome and WikiPathways.  
Red = upregulated; Green = downregulated.
PATHWAYS GENES PC3 DU145
AFFYMETRIX RT-PCR AFFYMETRIX RT-PCR
Cell cycle and apoptosis
BIRC5 −5.03 −27.03 – 1.1
BRCA1 3.49 2.79 2.37 3.45
BRCA2 2.92 1.5 1.66 3.35
BUB1 −5.79 −3.94 1.4 1.84
CCNA2 −17.07 −15.38 – 1.64
CDC20 −8.08 −5.38 – 1.14
CDC25C −4.6 −9.26 −1.09 −1.08
CDC6 −9.88 −2.98 −1.81 −2.35
CDK1 −13.02 −8.93 1.65 1.69
CDKN3 −6.57 −3.61 −1.26 1.37
EGF −1.76 −2.86 −2.02 −3.31
FGF2 2.03 3.05 2.23 2.41
MCM4 −2.4 1.3 −1.84 1.74
PLK1 −2.39 −7.81 – 1.04
PTTG1 −6.88 −6.85 −1.24 −1.26
RAD51 −2.98 −5.78 – −2.33
SMAD6 −2.3 −1.12 −2 −1.66
TGFB2 −2.15 1.31 −4.65 −1.22
Immune and inflammation
IFITM1 3.6 1.46 −8.12 −11.76
IL24 3.83 5.05 9.35 16.57
IRF1 2.24 3.14 2.34 2.06
S100A9 −2.02 −1.56 −4.27 −4.39
STAT1 −2.44 1.4 −1.4 −1.06
metastasis and tumor 
progression
ANGPTL4 2.99 16.49 3.73 9.29
ATF3 2.03 5.93 2.44 2.25
CDH11 4.8 – – –
CYP1B1 4.28 18.39 2.76 4.49
SOX4 2.05 8.18 – 2.32??? ?????? ???????? ??????????????????????????????????????????????????????????? ??? ?????
Figure 7. Western blot analysis of protein expression levels in PC3 and DU145 cell lines after treatment with GWh, WhO, and media only (no treatment control).
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inhibitions. Studies have found that malt whiskey may poten-
tially inhibit cancer development by increasing the antioxidant 
content in humans.40,41 When adjusted for the liquor-only 
counterpart, G. lucidum still showed strong observable growth 
inhibitory properties in both the cancerous cell lines. This 
suggests that G.  lucidum extracts have growth inhibitory 
effects in cancer cell lines and may have potential anticancer 
properties.
Most biologically active compounds in G. lucidum can be 
extracted with water or ethanol.8,15,42 It is possible that GRW 
and GWh contain active ingredients of both G. lucidum water- 
and ethanol-based extracts, as both types of liquors contain 
ethanol and water solvents. Therefore, consuming G. lucidum 
liquor extracts may potentially have a more valuable effect 
than using only ethanol-based or water-based extracts for use 
as an anticancer agent.
Affymetrix gene expression analysis. Our results indi-
cate  that over 11,000 genes have statistically significant 
changes in their expression levels after treatment with GWh 
and GRW. This is suggestive of the fact that G.  lucidum 
extracts have a wide range of effects. Unlike traditional anti-
cancer drugs that target single pathways, G. lucidum extracts 
consist of a number of components that can potentially exert 
their anticancer activities through multiple biologically active 
pathways. This is important because tumor cells can mutate 
rapidly and develop immunity to drugs that target a single 
pathway.43
GWh demonstrated a strong influence on gene expres-
sion in the two PCa cell lines tested. Relatively few significant 
changes in gene expression were detected after treatment with 
GRW. This is consistent with the observation that the IC50 
dosages of GRW and rice wine-only extracts (Table 2) were 
similar.
In addition, GWh has influenced the gene expression 
levels in the noncancerous cell line, which suggests that GWh 
can have an effect on healthy cell lines. In the noncancerous 
cell line, pathway analysis showed that the genes that pro-
mote apoptosis were downregulated and the genes that inhibit 
apoptosis were upregulated by G. lucidum extract. This effect 
is observed only in the control noncancerous cell line, which 
suggests that the observed effects may promote survival in 
healthy cells. This observation corresponds with the studies 
conducted by Cherian et al and Ajith et al, who showed that 
G. lucidum promotes longevity.44,45
Pathway analysis. The development of cancerous cells is 
a multistep process involving normal cells, acquiring several 
hallmarks of cancer to evolve to a neoplastic state.43 These bio-
logical capabilities of malignant cells can be targeted for the 
treatment of cancer.
Treatment with G.  lucidum-based extracts resulted in 
changes in the gene expression levels of various genes associ-
ated with a number of different biologically active pathways 
(Tables 4 and 5). The use of the Affymetrix array permitted 
the simultaneous characterization of the expression levels of 
a large number of genes. This aided in the examination and 
discovery of biologically active pathways associated with the 
anticancer activity of G. lucidum.
Cell cycle and apoptosis. Treatment of cancerous cell 
lines with G.  lucidum extracts resulted in changes in gene 
expression associated with cell cycle and DNA replication. 
Cell cycle is a process by which cells divide and proliferate; 
thus, in order to control the deregulated growth of cancer 
cells,43 various anticancer compounds, for example, flavonoids 
and paullones, can be used that act by inhibiting the cell cycle 
pathway.46 However, drugs that inhibit DNA replication, 
such as azathioprine, fail to completely eradicate cancer cells 
?? ????????????????????????????????????????????????????? ????? ????? ???? ???? ?????? ??????????????????????? ??????????????????
Figure 8. Comparison of the fold changes in gene/protein expression levels of six genes and their related proteins in PC3 cell lines after treatment with 
G. lucidum whiskey extract. Affymetrix and RT-PCR analyses were used for the measurement of gene expression levels and Western blotting was used 
for the measurement of protein expression levels.
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and are often not only associated with a high level of toxicity 
but can also lead to the development of drug resistance in can-
cer cells.47
Affymetrix array analysis and pathway analysis were used 
to identify genes associated with cell cycle control. Genes 
such as the CDKs, which are upregulated during cell cycle 
in normal and cancerous cells,39 were found to be downregu-
lated after treatment with GWh in PCa cell lines (Table 6). 
This indicates that the amount of cells undergoing cell cycle 
progression is decreased, which contributes to the observed 
growth inhibitory effects.
Apoptosis is important for the maintenance of multicel-
lular life. It allows cells to initiate controlled cell death for 
the benefit of the organism as a whole by removal of older, 
less efficient cells and elimination of damaged and/or virally 
infected cells.48,49 Cancer cells deregulate apoptosis either 
through the overexpression of antiapoptotic proteins or 
through the action of mutations that reduce the efficiency 
of or completely remove proapoptotic proteins.48,49 The final 
process of apoptosis involves the activation of a series of cas-
pases known as the caspase cascade.18,19 In the PC3 cell line 
treated with GWh, the gene expression levels of the pro-
apoptotic caspases are found to be upregulated, which sug-
gests the activation of the caspase cascade that would in turn 
trigger apoptosis. The activation of the caspase cascade with 
G. lucidum extracts has been observed in other studies involv-
ing various cancer cell lines, including oral mucosal cancer 
and colorectal cancer.14,15 This effect seems to be cancer spe-
cific as it was not observed in the noncancerous control cell 
line, HEK293. This is important to note as various cytotoxic 
drugs that promote apoptosis in cancer cells can also cause 
apoptosis in healthy cells, which contributes to the acute side 
effects observed from cytotoxic drugs.50 The observation that 
the apoptotic effect of GWh is cancer specific suggests that it 
may be used specifically for cancer therapy without producing 
severe toxicity in humans.
In HEK293 cell line, GWh increased the expression of 
antiapoptotic genes such as CDK1. This suggests that GWh 
may promote cell survival in healthy, noncancerous cells and 
may contribute to the antiaging health benefits associated 
with G.  lucidum. This finding is consistent with studies that 
have reported G. lucidum to promote antioxidant activities and 
reduce aging.44,45 The observed protective effects of G. lucidum 
in healthy cells can be used in conjunction with cytotoxic 
drugs, as it reduces the apoptotic rate of normal cells triggered 
by cytotoxic drugs,9,26 and thus may offer a higher level of pro-
tection for normal cells.
Tumor immunity and progression. Inflammation and 
immunity are two closely linked biological pathways.51 Both 
pathways play a key role in the development and progres-
sion of tumors.52 Various studies have found that G. lucidum 
polysaccharide extracts can promote the immune system, 
in particular, antitumor immunity that promotes immune-
mediated killing of tumor cells.23–26 Using the GATHER 
pathway analysis, we found that GWh influenced the genes 
associated with the inflammatory and immune response 
(Fig. 6), in particular, the upregulation of genes associated 
with the activation of T-helper lymphocytes that are required 
to mount an effective immune response.53 Therefore, 
G.  lucidum extracts may potentially promote immunity via 
stimulation of T-helper cells. However, as the cell lines used 
are not immune cells, additional studies using immune cells 
will be required to assess if G. lucidum extracts have immune-
activating abilities.
Furthermore, we identified that treatment with 
G.  lucidum extracts affects cell–cell adhesion and 
angiogenesis.54,55 Cell–cell adhesion involves the expression 
of proteins on the surface of the cell and controls the attach-
ment of one cell to another. Strong cell–cell adhesion reduces 
the risk of tumor cell detachment and, thus, reduces the 
risk of metastasis. A cell–cell adhesion protein CDH11 was 
found to have increased in expression after treatment with 
G. lucidum extracts. The increased CDH11 expression could 
promote cell–cell adhesion and reduce the risk of metastasis 
via cell detachment.56
Angiogenesis is a physiological process that involves the 
development of new blood vessels from preexisting vessels.57 
Tumor angiogenesis promotes tumor expansion by supplying 
essential nutrients and oxygen, and the increased blood flow 
increases the risk of metastasis. Thus, the suppression of these 
properties will decrease tumor invasive behaviors and reduce 
the risk of metastasis.20–22
Gene expression comparison with protein expression. 
We compared the expression levels of the 28 genes obtained 
by RT-PCR analysis with those obtained by Affymetrix array 
analysis to validate the accuracy of the Affymetrix analysis and 
assess the chance of false positives (ie, type-1 errors). Addi-
tionally, we selected 6 genes from the 28 tested genes in RT-
PCR and performed WB to determine if the changes in gene 
expression were translated to changes in their protein expres-
sion levels. The six selected genes are BRCA1, Rad51, CDH11, 
IL24, IRF1, and S100A9, which have statistically significant 
differences in their gene expression levels.
BRCA1 and Rad51 are tumor suppressor genes. BRCA1 
plays a major role in DNA damage repair and in the con-
trol of cell cycle.58 In PCa, BRCA1 directly interacts with 
androgen receptors and induces the expression of cyclin-
dependent kinase inhibitors, leading to inhibition of cell cycle 
and apoptosis.59,60 Affymetrix and RT-PCR analyses showed 
upregulation of BRCA1 gene expression in both PC3 and 
DU145 cell lines (Table 6). In addition, WB showed increased 
expression of protein expression levels that matches the 
increased gene expression levels (Table 6).
Rad51 is involved in the repair of DNA double-strand 
breakages.61 Overexpression of Rad51 results in a range of con-
sequences, including increased resistance to DNA damaging 
agents, disruption of the cell cycle, and increased apoptotic 
cell death.61 Overexpression of Rad51 is also associated with 
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aggressive PCa.62 After treatment with GWh, Rad51 gene 
expression was found to be downregulated in PC3 cells in 
both Affymetrix and RT-PCR analysis. WB also showed a 
decrease in the expression of Rad51 protein. In the DU145 cell 
line, Affymetrix analysis did not show any significant decrease 
in Rad51 gene expression after treatment with GWh. Never-
theless, RT-PCR and WB showed a decrease in the expression 
levels of Rad51 gene and protein, respectively (Table 6).
In the PC3 cell line, Affymetrix analysis showed 
increased CDH11 gene expression after treatment with GWh. 
However, RT-PCR failed to detect CDH11 expression levels 
in both PC3 and DU145 cell lines. CDH11 is involved in 
cell–cell adhesion and its increased expression in tumors is 
associated with a reduced risk of metastasis.56 WB showed an 
increase in the expression of CDH11 protein after the treat-
ment. This suggests that, even though RT-PCR failed to detect 
any expression, CDH11 levels are still positively increased by 
the treatment with G. lucidum extracts.
Protein expression of the gene S100A9 was found to be 
downregulated by GWh treatment in both PC3 and DU145 
cell lines. The same S100A9 is overexpressed in many cancer 
types such as breast, prostate, and lung cancers.63 Its expression 
is further upregulated by hypoxia, which is also common in 
tumors.64 Therefore, the observed downregulation of S100A9 
gene expression can potentially reduce inflammation. Other 
studies have also found that G.  lucidum extracts can down-
regulate proinflammatory cytokines; however, an alcohol form 
of G. lucidum extract had not been tested previously.65–67
Both the gene and protein expression levels of IL24 and 
IRF1 are upregulated after treatment with GWh (Table 6). 
The genes IL24 and IRF1 have tumor suppressive capabili-
ties that are associated with the Janus-activated kinase (JAK)/
signal transducers and activators of transcription (STAT) 
signaling.68,69 The JAK/STAT signaling pathway is crucial in 
the cytokine-mediated immune response and is involved in 
proliferation and apoptosis.70 IL24 can also induce apoptosis 
mediated through mitogen-activated protein kinase (MAPK) 
pathways.71 IL24 has been shown to induce apoptosis in vari-
ous cancer cell lines.72 Upregulation of IL24 and IRF1 has 
antiproliferative effects in breast and colorectal cancers.73–76 
This suggests that GWh can inhibit tumor proliferation and 
promote antitumor response through JAK/STAT and MAPK 
signaling pathways.
Conclusion
For the first time, the growth inhibitory activities of two 
G.  lucidum liquor-based extracts, namely, GWh and GRW, 
in human PCa cell lines and one noncancerous control cell 
line have been tested. We observed that GWh and GRW 
have positive growth inhibitory effects on cancerous cell 
lines. The growth inhibitory effects are stronger in G. lucidum 
extracts than their liquor-only counterparts. This shows that 
G. lucidum, when extracted using whiskey and rice wine, has 
growth inhibitory properties in cancer cells.
In addition, 28 genes and six proteins were selected based 
on the result of Affymetrix analysis and tested using RT-PCR 
and WB, respectively. We found that in the PCa cell lines, 
the gene expression levels were consistent between Affyme-
trix and RT-PCR analyses. Furthermore, WB showed that 
the protein expression levels were found to correspond to their 
respective gene expression levels. The results from the gene 
and protein expression analyses showed that the expression 
levels of the selected genes are strongly affected by treatment 
with GWh at both RNA and protein levels.
Using gene and pathway analyses, we identified sev-
eral biologically active pathways, including the apoptotic 
pathway associated with anticancer activities of GWh in 
PC3 and DU145 cell lines. The potential anticancer effects 
of G.  lucidum include inhibition of cell cycle, induction of 
apoptosis, and reduction of tumor progression. The biologi-
cally active pathways associated with both ethanol and water 
extracts of G.  lucidum were observed in response to GWh 
treatment, which suggests that GWh contains active ingredi-
ents from both water and ethanol components.
Future studies should focus on using metabolomic analy-
sis to identify the active ingredients in the G. lucidum extracts. 
In addition, this study investigated the effect of G. lucidum in 
a cell line model. Further studies should be based on an ani-
mal model that would allow for the examination of the bio-
availability of G. lucidum extracts and the complex interactions 
within the tumor microenvironment.
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Supplementary Table 1. Human PCa cell lines with their respective culture media and doubling times.
CELL LINE DESCRIPTION CULTURE MEDIA DOUBLING TIME
Pc3 Human prostate adenocarcinoma, obtained 
from bone metastasis
Minimum Eagle Media (MEM) + 10% of 
Fetal Calf Serum (FCS) + 1% of Penicillin/
Streptomycin/Glutamine (100 U/mL)  
(Morgate Biotech)
24 hours
DU145 Human prostate adenocarcinoma, obtained 
from brain metastasis
30 hours
heK293 Noncancerous human kidney cells, 
obtained from an embryo
24 hours
 
Supplementary Table 2. A list of the primary Abs used in WB, together with their molecular weights and dilution ratio (Abcam). Abs were diluted 
in 5 mL of 5% nonfat dry milk.
TARGET PROTEIN TYPE PREDICTED MOLECULAR WEIGHT DILUTION RATIO
S100A9 Mouse monoclonal 14 kDa 1:50
BRCA1 Mouse monoclonal 207 kDa 1:100
RAD51 Mouse monoclonal 37 kDa 1:100
iRF1 Mouse monoclonal 37 kDa 1:250
iL24 Mouse monoclonal 38 kDa 1:500
b-actin Mouse monoclonal 42 kDa 1:1000
cDh11 Mouse monoclonal 87 kDa 1:250
Supplementary Materials
